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a b s t r a c t
A 57-year-old woman with progressive amyotrophic lateral sclerosis (ALS) presented re-
peatedly with atypical chest pain over a period of 4 years. Her initially normal cardiac
troponin T (cTnT) value became progressively elevated during subsequent visits in the
absence of clinically overt heart disease, and in the absence of alternative explanations for
cTnT elevation. In this one patient there appeared to be a relationship between her rising
levels of cTnT and increasing severity of ALS.
# 2014 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights
reserved.




Cardiac troponin T (cTnT), a highly speciﬁc marker of
myocardial injury, must be interpreted in an individualized
clinical context as elevations of cTnT in the absence of
coronary artery disease are common [1]. Increased cTnT has
been described in patients with immune-mediated skeletal
myopathies [2], but whether amyotrophic lateral sclerosis
(ALS), the most common motor neuron disease, can elevate
cTnT remains unclear [3,4]. If this is the case, then
knowledge that cTnT may gradually increase in patients* Corresponding author at  : Division of Cardiovascular Diseases, Mayo      
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0010-8650/# 201  The Czech Society of Cardiology. Published by Else5with ALS may improve our understanding of the patho-
physiologic interactions in this devastating neuropathy,  and
it may help facilitate appropriate evaluation of these
patients who can on occasion also present with chest pain
and thus consideration of an acute coronary syndrome
(ACS).
Case report
A 57-year-old woman with medical history signiﬁcant for
controlled hypertension and diabetes, paroxysmal atrialClinic, 200 First Street SW, Rochester, MN 55905, USA.        
vier Sp. z o.o. All rights reserved..
Table 1 – cTnT levels at each presentation and correlating ALS symptoms. The cut-off value for cTnT was set on 99th
percentile of normal reference population which was 0.01 ng/mL.
Time since 1st evaluation (months) 0 4 20 44 49 50 52
ALS symptoms Dysarthria Dysphagia Dyspnea Ventilator dependent, s/p tracheostomy
Initial cTnT (ng/mL) <0.01 <0.01 0.07 0.05 0.08 0.09
3 h cTnT (ng/mL) <0.01 0.03 0.07 0.06 0.07 0.17
6 h cTnT (ng/mL) <0.01 0.02 0.04 0.10 0.07 0.14
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 3 2 0 – e 3 2 2 e321ﬁbrillation in the remote past, and treated obstructive sleep
apnea, presented with gradual increase in atypical chest pain
and dysarthria. Her serial cTnT values obtained to rule out ACS
were normal (Table 1 and Fig. 1), and her ECG as well as stress
echocardiography was unremarkable for ischemia. Four
months later she presented with dyspnea secondary to food
aspiration and with some atypical chest pain. While the
resting ECG remained unchanged, serial cTnT values during
this evaluation reached detectable levels at 3 and 6 h and
exceeded local criteria for a rising pattern (Table 1 and Fig. 1).
Her chest pain subsided and dyspnea resolved with non-
invasive respiratory support. With respect to patient's wishes
and recent negative echocardiography ﬁnding no further
cardiovascular testing was performed. At this time, progres-
sion of dysarthria and the occurrence of dysphagia led to a
comprehensive neurological evaluation, which established
the diagnosis of ALS. Gradually increasing dyspnea in theFig. 1 – Temporal evolution of cTnT levels over the period of 4 ye
normal reference population which was 0.01 ng/mL.following 3 years ultimately necessitated ventilator for
respiratory support.
At age 61, the patient again presented with atypical chest
pain, and serial cTnT were elevated (Table 1 and Fig. 1). Three
subsequent episodes of atypical chest pain occurring in the
following 10 months revealed similar cTnT ﬁndings with a rising
pattern of values, while her repeated ECG and wall motion on an
echocardiogram remained negative for ischemic changes.
Given her underlying comorbidities and the lack of evidence
for ACS, coronary angiography and treatment with dual long
term anti-platelet therapy were not pursued. Repeated assess-
ments of B-type natriuretic peptide, creatinine, white blood cell
count, and D-dimer were not suggestive of other possible causes
of cTnT elevations such as renal insufﬁciency, heart failure,
sepsis, or pulmonary embolism [5]. Atrial ﬁbrillation or other
arrhythmias were not recorded at any of the hospital admis-
sions despite extensive ECG monitoring in the emergency room.ars. The cut-off value for cTnT was set on 99th percentile of
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This report identiﬁes a possible connection between chronic
elevations in cTnT levels and the evolution of ALS symptoms
in a patient without overt clinical evidence of cardiovascular
disease, and it raises the need to further investigate this
phenomenon in other patients with progressive ALS. Although
there was little clinical information to suggest concomitant
cardiovascular disease, we cannot exclude the possibility
that this patient had clinically occult cardiac involvement either
due to ALS or due to some other cardiovascular abnormality and
she certainly had risk factors for the latter which would provide
the most parsimonious explanation for the cTnT elevations [6].
However, because it has now been shown that elevations in the
cTnT assay can occur due to proteins that exist in skeletal
muscle after injury [7], it may be that the elevations we observed
were due to ALS alone. Unfortunately, we did not obtain a
measurement of cardiac troponin I (cTnI) to help with this
analysis and the patient's status precluded additional investi-
gations. Thus, these ﬁndings are hypothesis generating at best.
However, if these elevations were indeed due to skeletal muscle
disease, it would represent one of the few times where an
increasing pattern of values was observed. If such a phenome-
non can occur, it will need to be taken into account in the care of
patients with ALS who may require evaluation with cardiac
troponin I assays which seem to avoid this problem [7].
Conclusion
This case highlights the novel observation that patients with
ALS may present with gradually elevated cTnT without
clinically overt heart disease. Further studies are needed to
provide a clearer understanding of whether this is a unique
case, a case where cardiac disease was missed or an important
caveat concerning the use of cTnT.
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